Therapeutic Potential of Complement Modulation

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2009 Dec 5

PMID 19960015

Citations 87

Authors

Eric Wagner

Michael M Frank

Affiliations

Soon will be listed here.

Abstract

The complement system is an essential component of innate immunity that has been more recently recognized as an unexpected player in various pathological states. These include age-related macular degeneration, atypical haemolytic uraemic syndrome, allergy, foetal loss, and axonal and myelin degradation after trauma. Its importance has also been recognized in physiological processes including haematopoietic stem cell homing to the bone marrow, liver regeneration and modulation of adaptive immune responses. Although the complement system has long been known to be involved in autoimmune and inflammatory diseases, few agents that target the complement system are currently approved for clinical use. However, renewed interest in modulating this system in various pathological conditions has emerged, and several agents are now in development.

Citing Articles

Exosomal-complement system activation in preeclampsia.

David M, Maharaj N, Krishnan A J Obstet Gynaecol Res. 2025; 51(3):e16255.

PMID: 40070019 PMC: 11897585. DOI: 10.1111/jog.16255.

Immunodeficiency: Complement disorders.

McMurray J, Schornack B, Weskamp A, Park K, Pollock J, Day W Allergy Asthma Proc. 2024; 45(5):305-309.

PMID: 39294906 PMC: 11441536. DOI: 10.2500/aap.2024.45.240050.

Assessing the causal relationship between plasma proteins and osteoporosis: novel insights into pathological mechanisms and therapeutic implications.

Wang L, Guo X, Qin J, Jin Z, Liu Q, Sun C Osteoporos Int. 2024; 35(11):1973-1987.

PMID: 39120624 DOI: 10.1007/s00198-024-07225-y.

Is the Complement System Dysregulated in Preeclampsia Comorbid with HIV Infection?.

Govender S, David M, Naicker T Int J Mol Sci. 2024; 25(11).

PMID: 38892429 PMC: 11172754. DOI: 10.3390/ijms25116232.

3-Acetyl-11-keto-β-boswellic Acid-Based Hybrids Alleviate Acetaminophen-Induced Hepatotoxicity in HepG2 by the Regulation of Inflammatory and Oxidative Stress Pathways: An Integrated Approach.

Elgazar A, El-Domany R, Eldehna W, Badria F ACS Omega. 2023; 8(42):39490-39510.

PMID: 37901542 PMC: 10601058. DOI: 10.1021/acsomega.3c05247.

References

Eisen D, Minchinton R . Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis. 2003; 37(11):1496-505. DOI: 10.1086/379324. View

Holers V . The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008; 223:300-16. DOI: 10.1111/j.1600-065X.2008.00641.x. View

Reis E, Falcao D, Isaac L . Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol. 2006; 63(3):155-68. DOI: 10.1111/j.1365-3083.2006.01729.x. View

Herbert A, Deakin J, Schmidt C, Blaum B, Egan C, Ferreira V . Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. J Biol Chem. 2007; 282(26):18960-8. DOI: 10.1074/jbc.M609636200. View

Holland M, Morikis D, Lambris J . Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs. 2004; 5(11):1164-73. View

Chen C, Boackle R . A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses. Clin Immunol Immunopathol. 1998; 87(1):68-74. DOI: 10.1006/clin.1997.4515. View

Trouw L, Roos A, Daha M . Autoantibodies to complement components. Mol Immunol. 2001; 38(2-3):199-206. DOI: 10.1016/s0161-5890(01)00043-8. View

Jokiranta T, Zipfel P, Fremeaux-Bacchi V, Taylor C, Goodship T, Noris M . Where next with atypical hemolytic uremic syndrome?. Mol Immunol. 2007; 44(16):3889-900. DOI: 10.1016/j.molimm.2007.06.003. View

Davis 3rd A, Mejia P, Lu F . Biological activities of C1 inhibitor. Mol Immunol. 2008; 45(16):4057-63. PMC: 2626406. DOI: 10.1016/j.molimm.2008.06.028. View

10.

Hepburn N, Chamberlain-Banoub J, Williams A, Morgan B, Harris C . Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Mol Immunol. 2007; 45(2):395-405. PMC: 2572221. DOI: 10.1016/j.molimm.2007.06.144. View

11.

Fritzinger D, Hew B, Thorne M, Pangburn M, Janssen B, Gros P . Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev Comp Immunol. 2008; 33(1):105-16. DOI: 10.1016/j.dci.2008.07.006. View

12.

Marom Z, Shelhamer J, Berger M, Frank M, Kaliner M . Anaphylatoxin C3a enhances mucous glycoprotein release from human airways in vitro. J Exp Med. 1985; 161(4):657-68. PMC: 2189058. DOI: 10.1084/jem.161.4.657. View

13.

Mitchell D, Kirby L, Paulin S, Villiers C, Sim R . Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lymphoid tissue. Mol Immunol. 2007; 44(11):2997-3004. DOI: 10.1016/j.molimm.2006.12.027. View

14.

Bureeva S, Andia-Pravdivy J, Kaplun A . Drug design using the example of the complement system inhibitors' development. Drug Discov Today. 2005; 10(22):1535-42. DOI: 10.1016/S1359-6446(05)03592-0. View

15.

Inal J, Hui K, Miot S, Lange S, Ramirez M, Schneider B . Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J Immunol. 2004; 174(1):356-66. DOI: 10.4049/jimmunol.174.1.356. View

16.

Kavanagh D, Richards A, Atkinson J . Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med. 2007; 59:293-309. DOI: 10.1146/annurev.med.59.060106.185110. View

17.

Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen H, Rieben R . C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med. 2002; 30(8):1722-8. DOI: 10.1097/00003246-200208000-00008. View

18.

Zipfel P, Heinen S, Jozsi M, Skerka C . Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2005; 43(1-2):97-106. DOI: 10.1016/j.molimm.2005.06.015. View

19.

Kim D, Song W . Membrane complement regulatory proteins. Clin Immunol. 2005; 118(2-3):127-36. DOI: 10.1016/j.clim.2005.10.014. View

20.

Thielmann M, Marggraf G, Neuhauser M, Forkel J, Herold U, Kamler M . Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg. 2006; 30(2):285-93. DOI: 10.1016/j.ejcts.2006.04.022. View